Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. (Q54631608)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 June 2012

Language	Label	Description	Also known as
English	Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.	scientific article published on 3 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

N Kentepozidis

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

A Soultati

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

S Giassas

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

N Vardakis

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

A Kalykaki

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

A Kotsakis

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

E Papadimitraki

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

N Pantazopoulos

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

V Bozionellou

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

V Georgoulias

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

publication date

3 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

70

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

161-168

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Androgen receptor as a target in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Second-line chemotherapy for prostate cancer: patient characteristics and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Taxane refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1896-9

21 January 2018

Identifiers

10.1007/S00280-012-1896-9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/22660737

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54631608&oldid=2212542119"